217 related articles for article (PubMed ID: 32052404)
21. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review.
Shaheen N; Ransohoff DF
JAMA; 2002 Apr; 287(15):1972-81. PubMed ID: 11960540
[TBL] [Abstract][Full Text] [Related]
22. Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?
Inadomi JM; Saxena N
Dig Dis Sci; 2018 Aug; 63(8):2094-2104. PubMed ID: 29948571
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics of young patients with early Barrett's neoplasia.
Iwaya Y; Shimamura Y; Goda K; Rodríguez de Santiago E; Coneys JG; Mosko JD; Kandel G; Kortan P; May G; Marcon N; Teshima C
World J Gastroenterol; 2019 Jun; 25(24):3069-3078. PubMed ID: 31293342
[TBL] [Abstract][Full Text] [Related]
24. Screening and surveillance for complications related to gastroesophageal reflux disease.
Spechler SJ
Am J Med; 2001 Dec; 111 Suppl 8A():130S-136S. PubMed ID: 11749938
[TBL] [Abstract][Full Text] [Related]
25. Screening for Barrett's Esophagus: Balancing Clinical Value and Cost-effectiveness.
Patel A; Gyawali CP
J Neurogastroenterol Motil; 2019 Apr; 25(2):181-188. PubMed ID: 30827080
[TBL] [Abstract][Full Text] [Related]
26. AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.
Sharma P; Shaheen NJ; Katzka D; Bergman JJGHM
Gastroenterology; 2020 Feb; 158(3):760-769. PubMed ID: 31730766
[TBL] [Abstract][Full Text] [Related]
27. LOW PREVALENCE OF BARRETT'S ESOPHAGUS IN A RISK AREA FOR ESOPHAGEAL CANCER IN SOUTH OF BRAZIL.
DE Carli DM; Araujo AF; Fagundes RB
Arq Gastroenterol; 2017 Dec; 54(4):305-307. PubMed ID: 28954045
[TBL] [Abstract][Full Text] [Related]
28. Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy.
Thota PN; Vennalaganti P; Vennelaganti S; Young P; Gaddam S; Gupta N; Lieberman D; Sampliner R; Falk GW; Mathur S; Kennedy K; Cash BD; Moawad F; Bansal A; Spaander MC; Bruno MJ; Vargo J; Sharma P
Gastroenterology; 2017 Apr; 152(5):987-992. PubMed ID: 27988383
[TBL] [Abstract][Full Text] [Related]
29. [The Chinese consensus for screening, diagnosis and management of Barrett's esophagus and early adenocarcinoma(2017, Wanning)].
; ;
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):701-711. PubMed ID: 28870046
[TBL] [Abstract][Full Text] [Related]
30. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy.
Rubenstein JH; Inadomi JM; Brill JV; Eisen GM
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):312-8. PubMed ID: 17368230
[TBL] [Abstract][Full Text] [Related]
31. [Gastroesophageal reflux disease and malignancy].
Richert Z; Robaszkiewicz M
Rev Prat; 2008 Sep; 58(13):1414-5, 1417, 1419-20. PubMed ID: 18924321
[TBL] [Abstract][Full Text] [Related]
32. Risk factors and populations at risk: selection of patients for screening for Barrett's oesophagus.
Rubenstein JH; Thrift AP
Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):41-50. PubMed ID: 25743455
[TBL] [Abstract][Full Text] [Related]
33. Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial.
Old O; Moayyedi P; Love S; Roberts C; Hapeshi J; Foy C; Stokes C; Briggs A; Jankowski J; Barr H;
J Med Screen; 2015 Sep; 22(3):158-64. PubMed ID: 25767103
[TBL] [Abstract][Full Text] [Related]
34. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
35. The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: a 1-year cross-sectional study in a referral area with 260,000 inhabitants.
Mäntynen T; Färkkilä M; Kunnamo I; Mecklin JP; Juhola M; Voutilainen M
Am J Gastroenterol; 2002 Oct; 97(10):2524-9. PubMed ID: 12385433
[TBL] [Abstract][Full Text] [Related]
36. Management of Barrett's esophagus: cases and questions.
Bresalier R
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S2-5. PubMed ID: 16399421
[TBL] [Abstract][Full Text] [Related]
37. Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
Weusten BLAM; Barret M; Bredenoord AJ; Familiari P; Gonzalez JM; van Hooft JE; Ishaq S; Lorenzo-Zúñiga V; Louis H; van Meer S; Neumann H; Pohl D; Prat F; von Renteln D; Savarino E; Sweis R; Tack J; Tutuian R; Martinek J
Endoscopy; 2020 Jun; 52(6):498-515. PubMed ID: 32375192
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
Gerson LB; Groeneveld PW; Triadafilopoulos G
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
[TBL] [Abstract][Full Text] [Related]
39. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus.
Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A
Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675
[TBL] [Abstract][Full Text] [Related]
40. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
